Rights Trading Commences

Imagion Biosystems Limited (ASX:IBX) is pleased to confirm that the rights the subject of the Company’s Renounceable Rights Issue announced on Wednesday, 25…


Change to Board of Directors — Director Resignation

Imagion Biosystems Limited has accepted the resignation of non-executive director Bronwyn Le Grice. Ms Le Grice's resignation is effective March 31st, 2020.…


Renounceable Rights Issue Prospectus

Imagion Biosystems Limited has released the Renounceable Rights Issue Prospectus: For a renounceable pro rata offer of 204,512,879 Shares at an issue price of…


Appendix 3B — Renounceable Rights Issue

Imagion Biosystems Limited has released Appendix 3B — Renounceable Rights Issue. Read Appendix 3B.


Pro-Rata Renounceable Rights Issue

Imagion Biosystems Limited has released "Pro-Rata Renounceable Rights Issue". Highlight of this issue include: Funds to complete the manufacture of…


Trading Halt

The securities of Imagion Biosystems Limited ('IBX') will be placed in trading halt at the request of IBX, pending it releasing an announcement. Unless ASX…


Change of Registered Address

Imagion Biosystems Limited wishes to advise that its Australian registered office address has changed with immediate effect to: c/o K&L Gates, Level 25,…


Investor Presentation — Imagion Biosystems MagSense™ Technology

President and CEO Bob Proulx today addressed investors at the Switzer Small and Microcap Investor Day in Sydney Australia. He discussed recent milestones,…


Appendix 4E and 2019 Full Year Results

Appendix 4E and 2019 Full Year Results Key Developments Achieved for MagSense™ Imaging Technology Imagion Biosystems has released its Appendix 4E and…


Business Update: Manufacturing Commences

Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to…